Powered by

APRINOIA Therapeutics Licenses Tau PET Imaging Tracer APN-1607 to Celgene

Jan 02, 2019 - PR Newswire

PR Newswire

APRINOIA Therapeutics, a clinical-stage biotechnology company developing therapeutics and diagnostic imaging tools for neurodegenerative diseases announced today that it has entered into a non-exclusive licensing agreement with Celgene Corporation. The agreement authorizes Celgene to use APN-1607, a novel investigational [18F]-labeled positron emission tomography (PET) imaging tracer, to support patient selection and efficacy evaluation in its global clinical trials. Under the ...